Interactions of antiepileptic drugs
- PMID: 50232
- DOI: 10.1111/j.1528-1157.1975.tb06065.x
Interactions of antiepileptic drugs
Abstract
Several interactions involving antiepileptic drugs are based on changes in the rate of their metabolism and elimination, with concomitant rise or fall of plasma levels. Thus, phenobarbital generally induces the production of the DPH metabolizing enzyme, but its presence inhibits the action of that enzyme. The net result depends upon the balance between these factors in individual patients. Either a decline, a rise, or no change of the DPH plasma level may occur after the onset of administration of phenobarbital. Drugs that may cause elevation of the DPH plasma level include disulfiram, sulthiame, bishydroxycoumarin, chloramphenicol, phenyramidol, benzodiazepines, sulfamethizole, and isoniazid. Isoniazid has been shown experimentally to be a strong inhibitor of DPH metabolism. The extent of DPH plasma level elevation by INH is related to the genetic make-up of individual patients. The highest and frequently toxic DPH plasma levels were seen in very slow INH inactivators. The incidence of clinically significant interactions is not high with most drug combinations; marked changes of antiepileptic drug levels occur only in apparently susceptible individuals. The effects of interactions are not necessarily detrimental; elevation of a low ineffective level may improve seizure control. A rise to a toxic level range requires reduction of the dose of primary drug or elimination of interfering drugs. Monitoring the blood levels of anti-epileptic drugs provides the best means to anticipate interactions and to regulate the doses when multiple medications have to be used.
Similar articles
-
Usefulness of blood levels of antiepileptic drugs.Arch Neurol. 1974 Nov;31(5):283-8. doi: 10.1001/archneur.1974.00490410031001. Arch Neurol. 1974. PMID: 4138035 Review. No abstract available.
-
The clinical pharmacology of antiepileptic drugs.Clin Neuropharmacol. 1984;7(1):1-34. doi: 10.1097/00002826-198403000-00001. Clin Neuropharmacol. 1984. PMID: 6423279 Review. No abstract available.
-
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.Clin Pharmacokinet. 1996 Sep;31(3):198-214. doi: 10.2165/00003088-199631030-00004. Clin Pharmacokinet. 1996. PMID: 8877250 Review.
-
Interactions between anticonvulsants.Proc Aust Assoc Neurol. 1975;12:111-6. Proc Aust Assoc Neurol. 1975. PMID: 2912
-
Pharmacologic interactions between valproate and other drugs.Am J Med. 1988 Jan 25;84(1A):29-33. doi: 10.1016/0002-9343(88)90054-x. Am J Med. 1988. PMID: 3146222
Cited by
-
Pharmacokinetic drug interactions with phenytoin (Part II).Clin Pharmacokinet. 1990 Feb;18(2):131-50. doi: 10.2165/00003088-199018020-00004. Clin Pharmacokinet. 1990. PMID: 2180613 Review. No abstract available.
-
Effect of diphenylhydantoin and its main hydroxylated metabolite on the pharmacokinetics and the urinary and biliary excretion of phenobarbital and its p-hydroxy metabolite.Eur J Drug Metab Pharmacokinet. 1981;6(2):99-108. doi: 10.1007/BF03189475. Eur J Drug Metab Pharmacokinet. 1981. PMID: 7306277
-
Anticonvulsant drugs. An update.Drugs. 1984 Apr;27(4):328-63. doi: 10.2165/00003495-198427040-00003. Drugs. 1984. PMID: 6327221 Review.
-
Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.Drug Saf. 1998 Dec;19(6):495-510. doi: 10.2165/00002018-199819060-00006. Drug Saf. 1998. PMID: 9880092 Review.
-
The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin.Br J Clin Pharmacol. 1982 Apr;13(4):501-5. doi: 10.1111/j.1365-2125.1982.tb01411.x. Br J Clin Pharmacol. 1982. PMID: 7066165 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources